1301 2nd Avenue
United States - Map
Dendreon Corporation, a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics to enhance cancer treatment options for patients. Its product portfolio includes active cellular immunotherapies and a small molecule product candidate that could be applicable to treating various types of cancers. The company offers PROVENGE, an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, and castrate-resistant prostate cancer. Its product candidates under research and development includes DN24-02, an investigational active cellular immunotherapy, which is in Phase II clinical trial for the treatment of patients with bladder, breast, ovarian, and other solid tumors expressing HER2/neu; carbonic anhydrase 9, an antigen expressed in renal cell carcinoma; carcinoembryonic antigen, an antigen expressed in colorectal and other cancers; and Transient Receptor Potential, sub-family M 8, a small molecule that has completed Phase I clinical trial to treat various types of cancers. Dendreon Corporation was founded in 1992 and is headquartered in Seattle, Washington. On November 10, 2014, Dendreon Corp. along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
|Dendreon Corp.’s ISS Governance QuickScore as of Nov 1, 2014 is 9. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 7; Compensation: 10.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Gregory R. Cox ,
Interim Chief Financial Officer, Principal Accounting Officer and Treasurer
|Mr. John H. Johnson ,
|Mr. W. Thomas Amick ,
Chief Exec. Officer, Pres and Director
|Mr. William J. Monteith ,
Exec. VP of Technical Operations
|Mr. Robert L. Crotty ,
Exec. VP, Gen. Counsel and Sec.
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|